Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06408961 · ClinicalTrials.gov registry record

EVOC - EVs in Obesity and Cardiometabolic Disease

A clinical trial of Cardiovascular Diseases, sponsored by Massachusetts General Hospital.

Recruiting
Registry status
100
Enrollment target
1
Study location

NCT06408961: Recruiting study of Cardiovascular Diseases, sponsored by Massachusetts General Hospital.

NCT06408961 is a study of Cardiovascular Diseases that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 100 participants, below the 26,974-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT06408961, a study of Cardiovascular Diseases, is actively recruiting participants, sponsored by Massachusetts General Hospital.

RECRUITING
Registry status
100 participants
Enrollment target
1
Study location

Study Summary

The goal of this observational study is to research the impact of molecular signals from the heart, liver and fat tissue on cardiovascular disease risk, and the presentation of Type II Diabetes and diseases that affect the heart, blood vessels and metabolism (Cardiometabolic Disease). Specifically, the focus is on the content and function of Extracellular Vesicles (EVs), small sacs released from a cell's surface that contain important molecular cargo. The main questions it aims to answer are: 1. What molecular cargo do adipose-tissue EVs carry? 2. How do these cargo impact cardiac and hepatic function? 3. Are changes in EV content related to cardiac function and adiposity with weight loss? Tissue samples from fat tissue and blood samples will be collected from patients receiving bariatric weight loss surgery.

Primary Outcome

The study staff aim to obtain EVs from fat samples obtained at the time of bariatric weight loss surgery. The activity of genes within the cargo of the collected EVs are assessed using RNA sequencing and protein contents analysis. A statistical analysis performed utilizing computer technology will provide us with differentially expressed cargo that may be a step in the molecular communication pathway to the heart and liver tissues.

Conditions Studied

Study Locations (1)

Massachusetts

  • Massachusetts General Hospital - Boston

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2019-02-02
Est. Completion 2026-05-30
Massachusetts General Hospital

2,032 total trials

What NCT06408961 shows while recruiting

NCT06408961 is an observational study that tracks outcomes without assigning an intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 26,974-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (100% lower).

The record links to 1 condition, with Cardiovascular Diseases appearing as the primary indexed condition, and to 0 interventions.

NCT06408961 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT06408961 about?

NCT06408961 is a clinical study titled "EVOC - EVs in Obesity and Cardiometabolic Disease". The goal of this observational study is to research the impact of molecular signals from the heart, liver and fat tissue on cardiovascular disease risk, and the presentation of Type II Diabetes and diseases that affect the heart, blood vessels and metabolism (Cardiometabolic Disease). Specifically, ...

What is the current status of trial NCT06408961?

This trial is currently recruiting. The enrollment target is 100 participants. The study started on 2019-02-02. Estimated completion is 2026-05-30.

What conditions does trial NCT06408961 study?

This clinical trial studies the following conditions: Cardiovascular Diseases.

Who is sponsoring clinical trial NCT06408961?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06408961 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cardiovascular Diseases

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06408961's enrollment target sits among peer trials

100 194th of 300 higher than 101 of 300 other Cardiovascular Diseases trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cardiovascular Diseases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01048281 · 100 participants

    Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma

  • NCT01161199 · 100 participants

    The Use of Leukapheresis to Support HIV Pathogenesis Studies

  • NCT01327690 · 100 participants · Early Phase 1

    Mental Health in Veterans and Families After Group Therapies

  • NCT01730781 · 100 participants

    Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06408961, the US trial registry maintained by the National Library of Medicine. NCT06408961 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.